Treatment of cancer of the brain using histone deacetylase inhibitors
US7879865B2 · kind B2 · utility
4Cited by
26References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2005 |
| Grant date | Feb 1, 2011 |
| Priority date | — |
| Expiry date | Nov 18, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application is directed to a method of treating diseases of the central nervous system (CNS) comprising administering to a individual in need of treatment a therapeutically effective amount of an inhibitor of histone deacetylase. In particular embodiments, the CNS disease is a neurodegenerative disease. In further embodiments, the neurogenerative disease is an inherited neurodegenerative disease, such as those inherited neurodegenerative diseases which are polyglutamine expansion diseases. The individual can be a mammal such as a primate or human.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.